Central Nervous System(CNS) Efficacy of Dacomitinib
This is a single-arm, phase II study of dacomitinib in advanced EGFR-mutant NSCLC patients who have non-irradiated brain metastasis.
Non Small Cell Lung Cancer|Brain Metastases
DRUG: Dacomitinib
CNS objective response rate (Complete response or Partial response), The rate of CR or PR of CNS disease, 1 year
CNS progression-free survival, Time from enrollment to CNS progression or death, 1 year|Cumulative incidence of CNS failure by competing risk analysis, To evaluate the CNS efficacy of dacomitinib, 1 year|Extracranial objective response rate, The rate of CR or PR, 1 year|Progression-free survival, Time from enrollment to progression or death, 1 year|Overall survival, Time from enrollment to death of any cause, 1 year|Safety by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, The % of side effect, 1 year
This is a single-arm, phase II study of dacomitinib in advanced EGFR-mutant NSCLC patients who have non-irradiated brain metastasis.